Delivery Order SPE2DB20D1100-SPE2DB25FD7N9
Award Date 7/31/25
Potential Completion Date 8/1/25
Potential Value $1.6K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,599.24 to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets in quantities of 30 units. This firm fixed-price, competitively awarded contract was issued on July 21, 2025, with an ultimate completion date of July 22, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. XELJANZ XR is a prescription pharmaceutical product used in the treatment of inflammatory...
- The Defense Logistics Agency awarded a delivery order valued at $5,053.83 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price, competitively awarded delivery order represents a routine pharmaceutical procurement under the company's existing contract vehicle with DLA. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $20,578.74 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on August 4, 2025, with an ultimate completion date of August 5, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location and serves as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $27,184.05 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a child contract. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. XELJANZ XR is a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) valued at $9,027.48 under a firm fixed-price contract type. The award was issued on July 28, 2025, with an ultimate completion date of July 29, 2025, and was competitively awarded with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs,...
- The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract valued at $5,239.68 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of XELJANZ XR 11 MG TABLET 30S. This order is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 awarded to AmerisourceBergen Drug Corp by DLA to provide a comprehensive range of pharmaceutical products and medical supplies to support military...
- The Defense Logistics Agency awarded a delivery order valued at $1,632.60 to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count units) on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price delivery order represents a non-competitive award under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp, headquartered in...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide XELJANZ XR 11 MG tablets. The $3,597.61 contract has a period of performance through March 14, 2024. AmerisourceBergen Drug Corp is the prime contractor, and the contract does not have any set-aside designations. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,874.93 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order was not set-aside and represents a competitive award under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,491.03 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 MG tablets (30-count units). This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by July 22, 2025. The contract represents a single transaction under AmerisourceBergen's larger pharmaceutical supply agreement with the federal government, with performance taking place at the...